LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

LLY

778.49

+1.1%↑

JNJ

152.25

+0.62%↑

NVO

70.68

+1.29%↑

ABBV

185.54

+0.9%↑

UNH

305.52

+1.55%↑

Search

Crinetics Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

30.83 3.32

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

29.05

Massimo

31.4

Metriche Chiave

By Trading Economics

Entrata

-16M

-97M

Vendite

361K

361K

EPS

-1.04

Margine di Profitto

-26,807.202

Dipendenti

437

EBITDA

-17M

-110M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+145.36% upside

Dividendi

By Dow Jones

Utili prossimi

7 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-185M

3B

Apertura precedente

27.51

Chiusura precedente

30.83

Notizie sul Sentiment di mercato

By Acuity

50%

50%

168 / 380 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Weak Bullish Evidence

Crinetics Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

24 giu 2025, 23:49 UTC

Acquisizioni, Fusioni, Takeovers

Xero to Buy Melio for Initial US$2.5 Billion in U.S. Growth Play -- Update

24 giu 2025, 23:39 UTC

Azioni calde

Stocks to Watch: Torrid Holdings, FedEx, QuantumScape

24 giu 2025, 22:58 UTC

Utili

FedEx Shares Mixed Outlook as Tariffs Roil International Customers -- 2nd Update

24 giu 2025, 22:37 UTC

Acquisizioni, Fusioni, Takeovers

Xero Acquires Melio for Initial US$2.5 Billion in U.S. Growth Play

24 giu 2025, 23:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

24 giu 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Trade Rangebound Amid Middle East Uncertainty -- Market Talk

24 giu 2025, 23:40 UTC

Discorsi di Mercato

Gold Steady Amid Fed Rate-Cut Prospects -- Market Talk

24 giu 2025, 23:18 UTC

Discorsi di Mercato

Briscoe Rallies Too Hard for Forsyth Barr -- Market Talk

24 giu 2025, 23:07 UTC

Discorsi di Mercato

Australian Inflation Data Set to Green Light RBA Cut -- Market Talk

24 giu 2025, 23:06 UTC

Discorsi di Mercato

Reliance Worldwide's U.S. Headwinds to Remain into FY26 -- Market Talk

24 giu 2025, 23:05 UTC

Utili

FedEx Posts Growth, Mixed Outlook Amid Tariffs and Inflation -- 2nd Update

24 giu 2025, 23:04 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

24 giu 2025, 23:04 UTC

Discorsi di Mercato

FedEx to Feel Pressure From De Minimis Exemption Ending -- Market Talk

24 giu 2025, 22:57 UTC

Discorsi di Mercato

Australia's Chalmers in Critical Talks With Bessent -- Market Talk

24 giu 2025, 22:55 UTC

Discorsi di Mercato

Unpredictable Trade Policy Keeps FedEx Outlook Narrow -- Market Talk

24 giu 2025, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Krafton Is a South Korean Videogame Developer

24 giu 2025, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Woodside CEO Says Strong Interest Remains From Potential Partners in Louisiana LNG

24 giu 2025, 22:54 UTC

Acquisizioni, Fusioni, Takeovers

Krafton: Acquisition Aims to Diversify Business in Japan

24 giu 2025, 22:54 UTC

Acquisizioni, Fusioni, Takeovers

Krafton: K.K. BCJ-31 Is Parent of Advertising-Animation Group ADK Holdings

24 giu 2025, 22:54 UTC

Acquisizioni, Fusioni, Takeovers

Krafton Acquires Japan's K.K. BCJ-31 for KRW710.37B

24 giu 2025, 22:54 UTC

Acquisizioni, Fusioni, Takeovers

Woodside Energy Completes Sale of 40% Stake in Louisiana LNG Infrastructure to Stonepeak

24 giu 2025, 22:14 UTC

Acquisizioni, Fusioni, Takeovers

Xero: Acquisition of Bill-Pay Provider Meets Critical U.S. Customer Need

24 giu 2025, 22:11 UTC

Acquisizioni, Fusioni, Takeovers

Xero Sees Opportunity to More Than Double Revenue by FY28

24 giu 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

Xero Expects Combined Business to Significantly Accelerate U.S. Revenue Growth

24 giu 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

Xero Expects to Keep Generating Positive Cash-Flow Following Transaction

24 giu 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

Xero To Acquire Melio, A Leading US SMB Bill Pay Solution, To Accelerate Global Growth >XRO.AU

24 giu 2025, 22:09 UTC

Acquisizioni, Fusioni, Takeovers

Xero: Up-Front Consideration Values Melio at 13.4 Times Annualized Revenue

24 giu 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Xero to Use US$600 Mln of Existing Cash on Balance Sheet

24 giu 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Xero to Use US$400 Mln Unsecured Revolving Credit Facility

24 giu 2025, 22:08 UTC

Acquisizioni, Fusioni, Takeovers

Xero to Give US$360 Mln in Stock to Melio Shareholders

Confronto tra pari

Modifica del prezzo

Crinetics Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

145.36% in crescita

Previsioni per 12 mesi

Media 74 USD  145.36%

Alto 97 USD

Basso 53 USD

Basato su 8 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Crinetics Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

8 ratings

8

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

30.39 / 33.46Supporto e resistenza

A breve termine

Weak Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

168 / 380 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.